MedTrace Logo

Clinical Study of FB1001 in Patients

NCT06506305 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2024-07-17

No results posted yet for this study

Summary

This study is designed for single-center, open-label, dose escalation phase I trial to evaluate the safety and tolerability of a single/multiple intravitreal injection of FB1001 in patients with APACG(Acute Primary Angle-Closure Glaucoma) or NAION(Nonarteritic Anterior Ischemic Optic Neuropathy).

Conditions

  • Optic Neuropathy
  • NAION - Non-Arteritic Ischemic Optic Neuropathy
  • APAC - Acute Primary Angle Closure
  • Glaucoma, Angle-Closure

Interventions

DRUG

FB1001

Intravitreal (IVT) injection

Sponsors & Collaborators

  • 4B Technologies Limited

    collaborator INDUSTRY

  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-15
Primary Completion
2026-06-30
Completion
2026-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06506305 on ClinicalTrials.gov